Long-Term Effects of Mid-Dose Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Meta-analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The effect of ursodeoxycholic acid (UDCA) treatment on survival and liver histological progression of primary biliary cirrhosis (PBC) remains uncertain. The aim of this study is to assess the long-term efficacy of mid-dose UDCA treatment for PBC. METHODS: Electronic databases including Medline, Embase, Cochrane controlled trials register, Science Citation Index, and PUBMED (updated to Nov 2005), and manual bibliographical searches were conducted. A meta-analysis of all long-term randomized controlled trials (RCTs) comparing mid-dose UDCA with placebo or no treatment was performed. RESULTS: Seven RCTs and six reports of their extended follow-up including 1,038 patients were assessed. UDCA could significantly improve liver biochemistry, but had no effect on pruritus and fatigue. UDCA could delay the progression of PBC, especially for early-stage patients. Meta-analysis of the seven RCTs including their extended follow-up showed a significant reduction of the incidence of liver transplantation (OR 0.65, p = 0.01), and a marginally significant reduction of the rate of death or liver transplantation (fixed-effect model: OR 0.76, p = 0.05; random-effect model: OR 0.77, p = 0.3) in the UDCA group, except death (OR 1.01, p = 1). In the sensitivity analyses, which included studies administrating placebo as control, long-term studies (> or = 48 months), or large size studies (total number of patients > or = 100), we all found long-term treatment with UDCA could significantly reduce the incidence of liver transplantation, and death or liver transplantation. CONCLUSIONS: Long-term treatment with mid-dose UDCA can improve liver biochemistry and survival free of liver transplantation in patients with PBC. In addition, UDCA therapy can delay the histological progression in the early-stage patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 2×
“A recent study (6) including 262 PBC patients treated with UDCA (13–15 mg/kg/day) of a mean period of 8 yr reported that the survival rates of these patients were lower than those of age- and sex-matched controls (RR = 1.4, p = 0.1), but better than survival rates without treatment, as estimated by the revised Mayo PB…”
MethodInfluentialA Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755 · cited 10×
“Poupon 1991(19) 3/3 NR 1/1 4/4 2/5 1/1 Heathcote 1994(20) 5/9 4/6 7/10 12/19 NR 4/6 Lindor 1994(21) 4/7 NR 3/5 7/12 1/5 0/0 Combes 1995(22) 3/3 NR 9/8 12/11 15/8 1/1 Vuoristo 1995(23) 0/2 0/1 0/3 0/5 NR 0/0 Pares 2000(24) 10/4 4/2 7/7 17/11 10/14 0/1 Papatheodoridis 2002(25) 17/14 13/11 6/3 23/17 22/19 NR”
BackgroundInfluentialPaumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748 · cited 2×
“The following selection criteria were applied: (1) study design: randomized, placebo, or untreated controlled trial; (2) study population: patients with PBC according to established diagnostic criteria (at least three of the following criteria: alkaline phosphatase [ALP] and (or gamma glutamyl transpeptidase [γ -GT] a…”
BackgroundMethodCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 8×
“Poupon 1991(19) 3/3 NR 1/1 4/4 2/5 1/1 Heathcote 1994(20) 5/9 4/6 7/10 12/19 NR 4/6 Lindor 1994(21) 4/7 NR 3/5 7/12 1/5 0/0 Combes 1995(22) 3/3 NR 9/8 12/11 15/8 1/1 Vuoristo 1995(23) 0/2 0/1 0/3 0/5 NR 0/0 Pares 2000(24) 10/4 4/2 7/7 17/11 10/14 0/1 Papatheodoridis 2002(25) 17/14 13/11 6/3 23/17 22/19 NR”
BackgroundInfluentialGoulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · cited 3×
“based on 11 RCTs including 1,272 patients showed no difference between UDCA and placebo in the incidence of death, liver-related death, liver transplantation, death, or liver transplantation (7).”
MethodInfluentialEffects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228 · cited 1×
“Poupon 1991(19) 2 2 3/3 1/1 4/4 Poupon 1994(35) 4 6/10 5/13 9/20 Heathcote 1994(20) 2 2 5/9 7/10 12/19 Kilmurry 1996(36) 6 20/17 15/22 35/39 Lindor 1994(21) 4 4 4/7 3/5 7/12 Lindor 1996(37) 7 NR† NR NR Jorgensen 2002(38) 12 14/23 14/19 28/42 Combes 1995(22) 2 2 3/3 9/8 12/11 Carithers 1996(39) 5 NR NR 27/29 Combes 200…”
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80136-6 · Cited by 134 · cited 2×
“Recent studies showed treatment with UDCA in mid-dose (11–20 mg/kg/day) had greater biliary enrichment and more pronounced effect on biochemical liver function tests than low-doses (≤10 mg/kg/day) (9, 10).”
BackgroundKilmurry, M. R., Heathcote, E. J., Cauch-Dudek, K., O’Rourke, K., Bailey, R. J., Blendis, L. M., Ghent, C. N., Minuk, G. Y., Pappas, S. C., Scully, L. J., et al. (1996) · Hepatology · doi:10.1002/hep.510230532 · Cited by 94 · cited 1×
“Poupon 1991(19) 2 2 3/3 1/1 4/4 Poupon 1994(35) 4 6/10 5/13 9/20 Heathcote 1994(20) 2 2 5/9 7/10 12/19 Kilmurry 1996(36) 6 20/17 15/22 35/39 Lindor 1994(21) 4 4 4/7 3/5 7/12 Lindor 1996(37) 7 NR† NR NR Jorgensen 2002(38) 12 14/23 14/19 28/42 Combes 1995(22) 2 2 3/3 9/8 12/11 Carithers 1996(39) 5 NR NR 27/29 Combes 200…”
Angulo, P., Jorgensen, R. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05270.x · Cited by 39
Research works printed but not linked: 31
- 10.1016/S0140-6736(03)13808-1 · DOI · Paper page
- 10.1016/S0168-8278(03)00192-2 · DOI · Paper page
- 10.1053/j.gastro.2004.11.009 · DOI · Paper page
- Gluud C, 2002, Cochrane Database Syst Rev, 1, CD000551
- 10.1046/j.1365-2036.1998.00395.x · DOI · Paper page
- Verma A, 1999, Eur J Gastroenterol Hepatol, 11, 1069, 10.1097/00042737-199910000-00001 · DOI
- 10.1053/he.2000.5984 · DOI · Paper page
- 10.1016/0197-2456(95)00134-4 · DOI · Paper page
- Kjaergard LL, 2001, Ann Intern Med, 135, 982, 10.7326/0003-4819-135-11-200112040-00010 · DOI · Paper page
- Shadish WR, The handbook of research synthesis, 1994, 261
- 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- 10.1016/0270-9139(94)90861-3 · DOI · Paper page
- 10.1016/0270-9139(95)90294-5 · DOI · Paper page
- 10.1016/0016-5085(95)90696-7 · DOI
- 10.1016/S0168-8278(00)80216-0 · DOI · Paper page
- 10.1111/j.1572-0241.2002.05923.x · doi:10.1111/j.1572-0241.2002.05923.x · Paper page
- Leuschner U, 1989, Gastroenterology, 97, 1268, 10.1016/0016-5085(89)91698-3 · DOI · Paper page
- Oka H, 1990, Gastroenterol Jpn, 25, 774, 10.1007/BF02779195 · DOI
- Senior JR, 1991, Falk Symp, 58, 273
- 10.1016/S0168-8278(05)80214-4 · DOI
- De la Mora G, 1994, Hepatology, 19, 57I
- Goddard CJR, 1994, Hepatology, 20, 151A
- Turner IB, 1994, J Gastroenterol Hepatol, 9, 162, 10.1111/j.1440-1746.1994.tb01237.x · DOI · Paper page
- Hwang SJ, 1993, J Gastroenterol Hepatol, 8, 217, 10.1111/j.1440-1746.1993.tb01189.x · DOI
- Eriksson LS, 1997, Scand J Gastroenterol, 32, 179, 10.3109/00365529709000190 · DOI · Paper page
- 10.1053/jhep.1996.v23.pm0008621147 · DOI
- 10.1111/j.1572-0241.2002.06043.x · doi:10.1111/j.1572-0241.2002.06043.x · Paper page
- Carithers JRRL, 1996, Gastroenterology, 110, A1163
- 10.1111/j.1572-0241.2004.04047.x · DOI · Paper page
- 10.1016/0270-9139(94)90144-9 · DOI
- 10.1016/S0168-8278(03)00243-5 · DOI
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Therefore, it was not surprising that meta-analyses which excluded studies of short duration (less than 24 months) and those that used an ineffective dose of UDCA (less than 10 mg/kg/d) concluded that long-term UDCA significantly improved transplant-free survival and delayed histologic progression in early-stage patie…”
BackgroundHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Metadata
- Authors
- Shi, J., Wu, C., Lin, Y., Chen, Y.-X., Zhu, L., & Xie, W.-F.
- Venue
- The American Journal of Gastroenterology
- Published
- 2006-07
- Volume
- 101
- Issue
- 7
- Pages
- 1529-1538
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2076436750
- Cited by
- 125
- References
- 14
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.